AtaiBeckley（ATAI）株式概要
臨床段階のバイオ製薬会社であるアタイ・ベックレー社は、米国、ドイツ、カナダでメンタルヘルス治療薬の研究、開発、商業化に従事している。 詳細
ATAI Community Fair Values
Create NarrativeSee what 47 others think this stock is worth. Follow their fair value or set your own to get alerts.
AtaiBeckley Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$4.33 |
| 52週高値 | US$6.75 |
| 52週安値 | US$1.89 |
| ベータ | 1.6 |
| 1ヶ月の変化 | -11.09% |
| 3ヶ月変化 | 11.60% |
| 1年変化 | 114.36% |
| 3年間の変化 | 144.63% |
| 5年間の変化 | n/a |
| IPOからの変化 | -77.74% |
最新ニュース
新しいナラティブ • May 17
ATAI: Advancing the Short-Acting Psychedelic Pivot via VLS-01 and the Clinical Maturation of Rapid-Acting Mental Health Therapeutics
atai Life Sciences (ATAI), particularly through its high-stakes Beckley atai joint venture (focusing on the lead asset BPL-003), is navigating a defining commercial breakout. The organization has successfully transitioned from an incubator holding company into a highly integrated clinical execution engine, aiming to solve the scalability bottleneck of psychedelic medicine.Seeking Alpha • Apr 08
AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD
Summary AtaiBeckley maintains a "Buy" rating, driven by key pipeline advances in psychedelic-based treatments for treatment-resistant depression. The company's BPL-003 achieved robust, rapid, and statistically significant reductions in MADRS scores in phase 2b, supporting upcoming parallel phase 3 ReConnection studies. The company secured FDA alignment for two pivotal phase 3 trials, with first patient dosing targeted for Q2 2026 and topline data expected in 2029. ATAI is well-capitalized with $220.7M in cash, sufficient to fund operations into 2029 and progress multiple TRD and neuroplastogen programs. Read the full article on Seeking AlphaRecent updates
新しいナラティブ • May 17
ATAI: Advancing the Short-Acting Psychedelic Pivot via VLS-01 and the Clinical Maturation of Rapid-Acting Mental Health Therapeutics
atai Life Sciences (ATAI), particularly through its high-stakes Beckley atai joint venture (focusing on the lead asset BPL-003), is navigating a defining commercial breakout. The organization has successfully transitioned from an incubator holding company into a highly integrated clinical execution engine, aiming to solve the scalability bottleneck of psychedelic medicine.Seeking Alpha • Apr 08
AtaiBeckley: 'Buy' On New Key Developments For BPL-003 For TRD
Summary AtaiBeckley maintains a "Buy" rating, driven by key pipeline advances in psychedelic-based treatments for treatment-resistant depression. The company's BPL-003 achieved robust, rapid, and statistically significant reductions in MADRS scores in phase 2b, supporting upcoming parallel phase 3 ReConnection studies. The company secured FDA alignment for two pivotal phase 3 trials, with first patient dosing targeted for Q2 2026 and topline data expected in 2029. ATAI is well-capitalized with $220.7M in cash, sufficient to fund operations into 2029 and progress multiple TRD and neuroplastogen programs. Read the full article on Seeking Alpha分析記事 • May 16
Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Apr 21
Atai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold Rating
Summary Initiate a Hold rating on Atai Life Sciences due to regulatory uncertainty and the need for robust, confirmatory Phase 2 and Phase 3 data. Atai's clinical pipeline includes promising treatments for mental health disorders, but regulatory pathways for psychedelic therapies remain unsettled, posing significant approval challenges. The market potential for Atai's therapies is substantial but crowded, with significant opportunities in treatment-resistant depression, social anxiety disorder, and cognitive impairment in schizophrenia. Atai's financial resources appear sufficient to fund key milestones into late 2026, but future funding needs and potential shareholder dilution are key risks. Read the full article on Seeking AlphaSeeking Alpha • Feb 27
Atai: Following The Path That Spravato Laid And Moving Beyond It
Summary Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato. Upcoming milestones and clinical trials. Psychedelic industry sentiment; RFK Jr influence. Read the full article on Seeking AlphaSeeking Alpha • Jan 29
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
Summary Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients, showing a 50% abstinence in patients over a 12-week period. Release of results from the phase 2b study using BPL-003 for treatment-resistant depression expected in mid-2025. The global treatment-resistant depression treatment market is projected to reach $4.06 billion by 2030. Atai's diversified pipeline includes RL-007 for cognitive impairment associated with schizophrenia, VLS-01 for TRD, and EMP-01 for social anxiety disorder, with key data readouts in 2025. Read the full article on Seeking AlphaSeeking Alpha • Sep 03
Psychedelic Stock Deep Dive: Atai Life Sciences
Summary After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure and diverse pipeline that could minimize risk. Atai's stock is at historic lows, but with several upcoming Phase 2 milestones, a long-term position in ATAI could be a smart move. Read the full article on Seeking Alpha分析記事 • Jul 15
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • May 27
ATAI: Enormous Potential Upside But No Clarity Yet
Summary Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase III data for COMP-360, are expected to impact the psychedelic drug industry. ATAI, an investment platform, offers cost control, diversification, and strategic investments, making it an attractive choice over COMPASS Pathways. Read the full article on Seeking Alpha分析記事 • Mar 02
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Oct 12
atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug
A drug from atai Life Sciences (NASDAQ:ATAI) based on an active component found in the plant kratom led to pain-relieving effects in an early-stage trial. The candidate, KUR-101, is an oral form of deuterated mitragynine, the major active alkaloid found in kratom. It is under investigation for opioid use disorder. Results showed that KUR-101 was safe and well-tolerated with a dose-proportional pharmacokinetic profile. Additional results, including comparing a single dose of KUR-101 to a single dose of oxycodone or placebo, is expected by the end of the year. Read why Seeking Alpha contributor Stephen Tobin is bullish on atai Life Sciences (ATAI).Seeking Alpha • Oct 06
Atai Life Sciences: Decentralized Drug Discovery Platform
Summary ATAI is at a value inflection point, it has slimmed its drug discovery pipeline and promises proof of concept data within two years. ATAI has taken on debt to give it a cash runway through to 2025, by which time it must have generated compelling evidence for its drugs. I believe three drugs under development have a good chance of success and will have a strong competitive position if approved. Atai Life Sciences (ATAI) has a somewhat unique business model, a decentralized platform that acquires and operates clinical programs that are separate companies or behave like them. It is a "company builder" I only know of two other companies with this model in the pharmaceutical industry BridgeBio (BBIO) and PureTech Health (PRTC). The recently appointed CFO of ATAI, Stephen Bardin, has moved to ATAI from BridgeBio. These companies have not done well of late. They are down 76% and 42%, respectively, with ATAI down 76% in the last 12 months. ATAI identifies promising mental health technologies or drugs and then acquires a stock interest, providing technical and financial support to hasten the time to market. ATAI companies are developing psychedelic and none-psychedelic compounds and technology for treating psychiatric disorders. ATAI current situation During the full year 2021 earnings call, ATAI talked about 13 drug development programs and four enabling technologies. In a recent press release, ATAI announced they had slimmed the drug development programs to 8 by focussing on the most promising programs that will generate meaningful data in the next two years. During the latest earnings call, we learned that ATAI had arranged a $175 million loan facility that brings total available cash to more than $300 million, extending its cash runway into 2025. However, by the end of 2025, the $300 million might have gone, and ATAI will likely have significant debt and most likely zero revenue. If an investment in ATAI is going to make money, then one of its eight drug programs must be a success. In this article, I will focus on the eight drug candidates under the ATAI umbrella, and a later article will look at the none drug products. The 8 ATAI drug programs hope to treat one of four mental health disorders. I will look at each disorder and evaluate the compounds being explored by ATAI, trying to judge their competitive situation. I will consider the evidence that they may be effective and safe and the potential market for the drug. None of the ATAI drugs will likely be approved within 3-5 years as all of their drugs are in phase I or II testing. However, all their candidates will release necessary proof of concept data within two years, and a good readout will lift the share price. ATAI was initially formed as an investment vehicle to invest in COMPASS Pathways (CMPS) and is a 24% shareholder in COMPASS. COMPASS Pathways is leading the way for psychedelic companies as it moves toward phase III testing. I previously wrote about COMPASS in-depth and will only consider it a competitor to ATAI when I assess the eight drug programs. Treatment-Resistant Depression Treatment Resistant Depression (TRD) has a significant unmet need; patients will have tried at least two previous treatments to be treatment resistive. ATAI has two drug candidates targeting this condition. COMPASS Pathways is about to take its Psilocybin-based compound to Phase 3 trial (we should get detail in mid-October) and has breakthrough therapy designation from the FDA, which should speed its path to approval. CMPS is leading the field for this condition and will likely be approved much earlier than any other compound. ATAI Candidate 1: PCN-101 PCN-101 is a patent-protected R-Ketamine compound. Ketamine is approved as a treatment for depression, and Numinus Wellness (NUMI) offers a wide range of Ketamine-assisted therapy in North America and Europe. The chemical structure of Ketamine is a mixture of two molecules, S-Ketamine and R-Ketamine. The FDA approved S-Ketamine for use with treatment-resistant depression in 2019; however, due to side effects, it must be administered in a clinic. The approval came with the following advisory. patients are at risk for sedation and difficulty with attention, judgment and thinking (dissociation), abuse and misuse, and suicidal thoughts and behaviors after administration of the drug. Because of the risk of sedation and dissociation, patients must be monitored by a health care provider for at least two hours after receiving their Spravato dose. ATAI believes that R-ketamine will be equally effective as S-Ketamine but without the side effects and could be approved for at-home use. This would be a significant advantage for the five or six million US adults that suffer from treatment-resistant depression. A search of available research suggests that R-Ketamine has greater potency and more prolonged lasting effects than S-Ketamine. ATAI Candidate 2: VLS-01 Derived from Ayahuasca, this hallucinogenic compound called N-Dimethyltryptamine ((DMT for short)) has a significant amount of study suggesting it is safe to use and an effective compound for altering mood. It has a very rapid onset but does require a clinic visit of about 2 hours, VLS-01 is being investigated for several other disorders. ATAI has recently dosed its first patient. I don't believe that the competitive situation for VLS-01 is as strong as PCN-101, as a psychedelic it requires clinical visits. Although research suggests it will be effective, it uses the same pharmacological mechanism as the other psychedelic drugs and may not offer any additional benefits. Other companies are also investigating TRD: Braxia Scientific (BRAX), have a phase II trial using Psilocybin to treat TRD and already have significant penetration of the general depression market through their KetaMD platform. GH Research has completed two phase I trials with GHoo1, proprietary and patent-protected 5-MeO-DMT-based compound with no severe side effects and more than 80% of patients reporting improved symptoms. 5-MeO-DMT is a naturally occurring psychedelic compound found in several plants in south America and at least one toad species. The value of PCN-101 is "at home use" it is the only drug currently in trial for this patient group that could potentially be administered at home. S-Ketamine, Psilocybin, and COMP360 require extensive clinic attendance. If it is successful in trials and ATAI can get it approved for at-home use it could be a huge seller. PCN-101 is currently in phase 2 testing. A readout from this study is expected in November 2022, and if positive, we could see a jump in share price and the start of a phase three trial. This is the first of the three compounds I think could be a success for ATAI. Anxiety Disorders Anxiety is a growing problem and is currently not well served pharmacologically. The market here could be huge; the US alone is thought to have more than 50 million people suffering the various forms of anxiety. The first line of drugs is usually SSRI (antidepressants), but these drugs are not well tolerated and are slow acting. Many patients fail to adhere to the dose, losing confidence in the drug, and as a result, they are considered somewhat ineffective. The second line of drugs is Benzodiazepines (like Xanax), these fast-acting and effective compounds come with significant risks of impaired cognition and sedation; they can be highly addictive. Outside of the US, a third treatment option exists. Etifoxine was developed in the 1960s as an alternative to drugs like valium. In 2000 French scientists discovered its dual action pharmacology which has led to the possibility of the drug being re-purposed as a cure to anxiety as it affects the GABA receptors in the brain. Etifoxine was approved many years ago in France, and more than 14 million subscriptions have been taken with zero addictions reported and a good safety standard generally. The drug was never introduced in the US or any other primary markets outside of France; it is already out of patent, so no business rationale exists for re-purposing it into other markets. ATAI Candidate 3: GRX-917 GRX-917 is a deuterated Etifoxine (change to the Hydrogen atoms that improves safety and effectiveness). It is a patent-covered formula currently in phase I testing by GABA Therapeutics. Early research suggests that GRX-917 will have the efficacy of Benzodiazepines without any side effects or risks of addiction. We know from the French experience that the drug is likely to be safe and effective. It is not a Psychadelic compound which may make the approval process more straightforward. Competition in this disorder is somewhat limited MindMed (MNMD) has a phase II trial using LSD (you can read my views on MindMed here). Incannex has a phase II study with Psilocybin, and Diamond Therapeutics have a Phase I with Psilocybin. GRX-917 appears to be the only non-psychedelic compound that may work in this area. A positive readout from the current trial (due next year) might result in a significant share price jump. Existing evidence for Etifoxine suggests that a positive readout is likely and that GRX-917 could be the blockbusting drug I am looking for and is the second compound I think could be a success. Cognitive Impairment Associated with Schizophrenia 80% of schizophrenia patients exhibit cognitive impairment ((CIAS)), and there is currently no approved treatment. The 24 million sufferers in the US cost medicare around $150 billion a year, and it is the 15th largest cause of disability. Recognify Life Science, ATAI controlled, is investigating the drug RL-007 and they have strong patents already approved. ATAI Candidate 4: RL-007 RL-007 (first developed and patented by Allergen now part of AbbVie in 2015 under the chemical formula (2R, 3S) -2-amino-3-hydroxy-3-pyridine-4-yl-1-pyrrolidine-1-yl-propane-1-one ((L)) - (+) - tartrate salt) is now exclusively licensed by Recognify. In December 2021, ATAI released the phase 2a data from 32 patients, showing significant improvement and supporting a more extensive trial. Two other drug companies Boehringer and Biogen have drugs in phase two trials for CIAS. It is just too early for me to predict the likely success of RL-007, as a relatively new compound, little research evidence exists, and it is impossible to know how it will stack up against the two competitors which are at the same stage of development. Substance Abuse The FDA has stated that: there currently are no products with demonstrated or purported reduced abuse liability on the market. As such, it represents a huge unmet need, and any successful drug will have a significant market.Seeking Alpha • Aug 15
ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01
ATAI Life Sciences press release (NASDAQ:ATAI): Q2 GAAP EPS of -$0.24 misses by $0.01. Cash, cash equivalents and short-term investments totaled $312.5 million as of June 30, 2022, compared to $362.3 million as of December 31, 2021.分析記事 • Aug 07
We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Jul 07
Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer
ATAI is backed by Peter Thiel. Its decentralized business model is pretty unique. I will wait for more data before I take a call on this very interesting company. Atai Life Sciences N.V. (ATAI) is a German-headquartered developer of medicines for mental health disorders. Atai is backed by billionaire investor Peter Thiel. It takes up compounds already known to be safe and effective in humans, as well as psychedelic compounds with known activity in humans, and then forms small affiliate companies around these drug candidates (it also forms affiliates to support some of its platforms, like intranasal delivery). The concept is novel, however, this is still at an early stage. The company's drug candidate pipeline looks like this: ATAI Pipeline (atai website) Lead program is PCN-101 / R-ketamine targeting Treatment Resistant Depression or TRD. Second program is RL-007 targeting Cognitive Impairment Associated With Schizophrenia. These two programs are currently running phase 2 trials. The company claims 17 active programs, four of which are "enabling technologies" focused on compound classes with prior evidence in humans, and 13 drug discovery programs in various stages. Atai operates in a decentralized manner. It has an affiliate of 18 small companies - some of these are listed in the diagram above. These companies, although decentralized, have access to shared resources, and are allocated capital accordingly. They have operational autonomy to develop compounds, with core guidance from the co-founders. I don't think I have seen exactly this model anywhere before. Lead indication is treatment-resistant depression, which is diagnosed after two failed doses of antidepressants. This amounts to a third of all depression patients. The economic burden of depression is huge, running into hundreds of billions of dollars. There are over 300 million people worldwide diagnosed with depression. There are very few treatment options. Only 6 drugs have been approved in the last 5 years. Atai has 2 clinical stage assets targeting TRD, and multiple preclinical ones. The most advanced asset is COMP360, which is being jointly developed with Compass Pathways (CMPS). Atai has a 22.5% stake. This asset toplined a phase 2b trial last year. In that study, COMP360 demonstrated efficacy in reducing depressive symptom severity with rapid and durable response. In November, the 25mg cohort from this study attained the primary endpoint. In a scale to measure the disease called MADRS, those who received 25mg showed a -6.6 difference vs. the comparator group at week 3 (p<0.001). COMP360 is an oral reformulation of Psilocybin, a psychoactive ingredient found in some species of "magic mushrooms." PCN-101, in which Atai has a 58.9% stake, completed a phase 1 study which showed safety and tolerability of R-ketamine at doses of up to 150mg. They now have a proof of concept phase 2 trial ongoing. Earlier, a phase 1 trial showed a distinct superiority of R-ketamine over S-Ketamine, suggesting that the former can be used at home. It was observed that the onset of dissociative and psychotomimetic effects occurred at fourfold higher doses than the equimolar doses of S-ketamine. The equivalent CADSS scores are from 12 to 15, scores that were observed in the 30mg and 60mg doses of PCN-101. The company has thus decided to use these two doses in the phase 2 trial. These doses may potentially be given at home. RL-007 has safety and tolerability data. An ongoing Phase 2 trial showed pro-cognitive potential of RL-007 in 180 patients with diabetic peripheral neuropathic pain. Earlier data also showed improvement in learning and memory. One good thing to Atai's approach of using previously-tested molecules is that they can use some of that old data in their trials. However, this may lead to lower competitive hurdles. Atai owns 51.9% of this asset. The company needs to work very hard to protect its intellectual property. The other assets lack any data at this time. FinancialsSeeking Alpha • Jun 30
atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO
Kures Therapeutics, an atai Life Sciences (NASDAQ:ATAI) appoints of Chad E. Beyer, Ph.D., MBA, as CEO of Kures succeeding Dr. Srinivas Rao, effective July 1, 2022. Dr. Srinivas Rao will continue to support and advise Kures’ programs from his role at atai Life Sciences. Most recently Dr. Beyer served as senior VP of Research and Development at Promentis Pharmaceuticals.Seeking Alpha • Jun 02
Atai Life Sciences N.V.: A First Take
Shares of mental health biopharma Atai Life Sciences N.V. have fallen some two-thirds from their June 2021 IPO pricing as the biotech market continues to crater. The company’s approach of identifying (in many instances psychedelic) compounds that have been tested in previous human trials marginally de-risks its programs. With the market placing a valuation of ~$210 million on ten of its 11 programs – many with blockbuster potential – the recent insider buying merited further investigation. A full investment analysis follows in the paragraphs below.Seeking Alpha • May 27
Atai Life Sciences And The Future Of Psychedelics For Mental Health
ATAI has a large portfolio of drugs, mainly psychedelics, that can be used to treat mental health conditions when other options have failed. There is ample room for new drug developments in this space, given that R&D for new drug developments has been declining. Success depends on legal changes, so it seems too early to initiate a position at the moment.分析記事 • Apr 22
We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...株主還元
| ATAI | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | 7.2% | -0.1% | -0.3% |
| 1Y | 114.4% | 38.7% | 26.7% |
業界別リターン: ATAI過去 1 年間で38.7 % の収益を上げたUS Pharmaceuticals業界を上回りました。
リターン対市場: ATAI過去 1 年間で26.7 % の収益を上げたUS市場を上回りました。
価格変動
| ATAI volatility | |
|---|---|
| ATAI Average Weekly Movement | 11.2% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: ATAI 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: ATAIの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2018 | 99 | Srini Rao | www.ataibeckley.com |
臨床段階のバイオ医薬品会社であるアタイベックレー・インクは、米国、ドイツ、カナダでメンタルヘルス治療薬の研究、開発、商業化に取り組んでいる。同社は、治療抵抗性うつ病（TRD）およびアルコール使用障害を対象に臨床第2a相および第2b相試験を実施中のメブホテニンの安息香酸塩形態の経鼻製剤BPL-003、統合失調症に伴う認知機能障害を対象に臨床第2b相試験を実施中の認知神経調節促進剤である経口生物学的利用可能化合物RL-007、および大うつ病性障害治療用のセロトニン作動性精神薬ELE-101を開発しています。また、TRD治療薬として臨床第2相試験中のN,N-ジメチルトリプタミン経口経粘膜フィルム製剤VLS-01、社交不安障害治療薬として臨床第2相試験中のR-3,4-メチレンジオキシメタンフェタミン経口製剤EMP-01、TRD治療薬として非幻覚性5-HT2A受容体作動薬EGX-AおよびEGX-Bを開発中である。さらに、シロシビン療法用のCOMP360、不安障害、うつ病、各種神経疾患の治療薬GRX-917も提供している。同社は以前はAtai Beckley N.V.として知られていたが、2025年12月に社名をAtaiBeckley Inc.に変更した。AtaiBeckley Inc.は2018年に設立され、ニューヨーク州ニューヨークに本社を置いている。
AtaiBeckley Inc. 基礎のまとめ
| ATAI 基礎統計学 | |
|---|---|
| 時価総額 | US$1.50b |
| 収益（TTM） | -US$663.40m |
| 売上高(TTM) | US$3.49m |
455.5x
P/Sレシオ-2.4x
PER（株価収益率ATAI は割高か？
公正価値と評価分析を参照収益と収入
| ATAI 損益計算書（TTM） | |
|---|---|
| 収益 | US$3.49m |
| 売上原価 | US$47.61m |
| 売上総利益 | -US$44.12m |
| その他の費用 | US$619.28m |
| 収益 | -US$663.40m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.81 |
| グロス・マージン | -1,264.91% |
| 純利益率 | -19,019.44% |
| 有利子負債／自己資本比率 | 0% |
ATAI の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 23:18 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
AtaiBeckley Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21
| アナリスト | 機関 |
|---|---|
| David Bouchey | Aegis Capital Corporation |
| Harry Gillis | Berenberg |
| Samuel England | Berenberg |